2895 related articles for article (PubMed ID: 19153164)
1. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
2. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
4. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
Mockenhaupt M; Kelly JP; Kaufman D; Stern RS;
J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522
[TBL] [Abstract][Full Text] [Related]
5. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.
Lin MS; Dai YS; Pwu RF; Chen YH; Chang NC
Intern Med J; 2005 Mar; 35(3):188-90. PubMed ID: 15737140
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.
Papay J; Yuen N; Powell G; Mockenhaupt M; Bogenrieder T
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):289-96. PubMed ID: 22139991
[TBL] [Abstract][Full Text] [Related]
7. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
[TBL] [Abstract][Full Text] [Related]
8. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
9. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.
Mockenhaupt M; Messenheimer J; Tennis P; Schlingmann J
Neurology; 2005 Apr; 64(7):1134-8. PubMed ID: 15824335
[TBL] [Abstract][Full Text] [Related]
10. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.
Sassolas B; Haddad C; Mockenhaupt M; Dunant A; Liss Y; Bork K; Haustein UF; Vieluf D; Roujeau JC; Le Louet H
Clin Pharmacol Ther; 2010 Jul; 88(1):60-8. PubMed ID: 20375998
[TBL] [Abstract][Full Text] [Related]
11. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
[TBL] [Abstract][Full Text] [Related]
12. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
Aberer W; Stingl G; Wolff K
Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
14. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
Gau SS; Chao PF; Lin YJ; Chang CJ; Gau CS
J Clin Psychopharmacol; 2008 Oct; 28(5):509-17. PubMed ID: 18794645
[TBL] [Abstract][Full Text] [Related]
15. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.
Schneck J; Fagot JP; Sekula P; Sassolas B; Roujeau JC; Mockenhaupt M
J Am Acad Dermatol; 2008 Jan; 58(1):33-40. PubMed ID: 17919775
[TBL] [Abstract][Full Text] [Related]
16. Anaphylaxis and toxic epidermal necrolysis or Stevens-Johnson syndrome after nonmucosal topical drug application: fact or fiction?
Sachs B; Fischer-Barth W; Erdmann S; Merk HF; Seebeck J
Allergy; 2007 Aug; 62(8):877-83. PubMed ID: 17620064
[TBL] [Abstract][Full Text] [Related]
17. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?
Tartarone A; Lerose R
Ther Drug Monit; 2010 Dec; 32(6):669-72. PubMed ID: 20844465
[TBL] [Abstract][Full Text] [Related]
19. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
20. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
